🕵️ Q32 BIO Inc. ($QTTB)
SEC insider & ownership activity, last 12 months · CIK 1661998 · every row links its SEC filing
Over the last 12 months insiders sold $217K against $30.0M of open-market buying. Orbimed Advisors LLC bought $15.0M in discretionary trades (May). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
2 buyers, $30.0M (4 lots) · 3 sellers, $217K (8 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 2 | $15.0M | 0 | – | May 28, 2026 |
| Xu Diyong | 2 | $15.0M | 0 | – | May 28, 2026 |
| Jodie Morrison | 0 | – | 3 | $141K | Feb 25, 2026 |
| Lee Kalowski | 0 | – | 3 | $57K | Feb 25, 2026 |
| Shelia M. Violette | 0 | – | 2 | $18K | Feb 25, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 13.9% | 13D | Jul 16, 2026 | filing ↗ | |
| Boxer Capital Management, LLC | 13.3% | 13G | Jul 10, 2026 | filing ↗ | |
| Boxer Holdings, LP | 13.3% | 13G | Jul 10, 2026 | filing ↗ | |
| Boxer Holdings GP, LLC | 13.3% | 13G | Jul 10, 2026 | filing ↗ | |
| Aaron Davis | 13.3% | 13G | Jul 10, 2026 | filing ↗ | |
| Orbimed Capital GP VII LLC | 11.8% | 13D | Jul 16, 2026 | filing ↗ | |
| BVF Partners L P/IL | 10.0% | 13G | Jun 4, 2026 | filing ↗ | |
| BVF INC/IL | 10.0% | 13G | Jun 4, 2026 | filing ↗ | |
| Mark N. Lampert | 10.0% | 13G | Jun 4, 2026 | filing ↗ | |
| Sirenia Capital Management LP | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Alex Silverstein | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| RA Capital Management, L.P. | 9.8% | 13G | Jun 4, 2026 | filing ↗ | |
| Peter Kolchinsky | 9.8% | 13G | Jun 4, 2026 | filing ↗ | |
| Rajeev Shah | 9.8% | 13G | Jun 4, 2026 | filing ↗ | |
| RA Capital Healthcare Fund, L.P. | 9.8% | 13G | Jun 4, 2026 | filing ↗ | |
| BVF GP Holdings LLC | 9.2% | 13G | Jun 4, 2026 | filing ↗ | |
| Opaleye Management Inc. | 8.6% | 13G | May 6, 2026 | filing ↗ | |
| Opaleye, L.P. | 8.6% | 13G | May 6, 2026 | filing ↗ | |
| James Silverman | 8.6% | 13G | May 6, 2026 | filing ↗ | |
| POINT72 Asset Management, L.P. | 5.7% | 13G | May 15, 2026 | filing ↗ | |
| POINT72 Capital Advisors, Inc. | 5.7% | 13G | May 15, 2026 | filing ↗ | |
| Steven A. Cohen | 5.7% | 13G | May 15, 2026 | filing ↗ | |
| Biotechnology Value Fund L P | 5.3% | 13G | Jun 4, 2026 | filing ↗ | |
| BVF I GP LLC | 5.3% | 13G | Jun 4, 2026 | filing ↗ | |
| The Carlyle Group Inc. | exited | 13G | Jul 6, 2026 | filing ↗ | |
| Carlyle Holdings I GP Inc. | exited | 13G | Jul 6, 2026 | filing ↗ | |
| Carlyle Holdings I GP SUB L.L.C. | exited | 13G | Jul 6, 2026 | filing ↗ | |
| Carlyle Holdings I L.P. | exited | 13G | Jul 6, 2026 | filing ↗ | |
| CG Subsidiary Holdings L.L.C. | exited | 13G | Jul 6, 2026 | filing ↗ | |
| TC Group, L.L.C. | exited | 13G | Jul 6, 2026 | filing ↗ | |
| Carlyle Investment Management L.L.C. | exited | 13G | Jul 6, 2026 | filing ↗ | |
| Carlyle Genesis UK LLC | exited | 13G | Jul 6, 2026 | filing ↗ | |
| Abingworth LLP | exited | 13G | Jul 6, 2026 | filing ↗ | |
| Abingworth Bioventures VII LP | exited | 13G | Jul 6, 2026 | filing ↗ | |
| Orbimed Genesis GP LLC | exited | 13D | Jul 16, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Jodie Morrison | $78K | Dec 2, 2025 | filing ↗ |
| Lee Kalowski | $31K | Dec 2, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Material agreement (1.01) | Jul 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 14, 2026 | filing ↗ |
| Other events (8.01) | Jul 13, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 13, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jul 13, 2026 | filing ↗ |
| Other events (8.01) | Jul 13, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 13, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 12, 2026 | filing ↗ |
| Material agreement (1.01) | May 26, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | May 26, 2026 | filing ↗ |
| Other events (8.01) | May 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 26, 2026 | filing ↗ |
| Earnings (2.02) | May 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 5, 2026 | filing ↗ |
| Other events (8.01) | Apr 24, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 24, 2026 | filing ↗ |
| Material agreement (1.01) | Mar 27, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 27, 2026 | filing ↗ |
| Earnings (2.02) | Mar 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 10, 2026 | filing ↗ |
| Material agreement (1.01) | Feb 17, 2026 | filing ↗ |
| Other events (8.01) | Feb 17, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 17, 2026 | filing ↗ |
| Officer/director changes (5.02) | Dec 17, 2025 | filing ↗ |
| Material agreement (1.01) | Nov 28, 2025 | filing ↗ |
| Agreement terminated (1.02) | Nov 28, 2025 | filing ↗ |
| Acquisition or disposition (2.01) | Nov 28, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 28, 2025 | filing ↗ |
| Other events (8.01) | Nov 28, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 28, 2025 | filing ↗ |